Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28536484 | 0.90 | ALOX15 (0.43) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL1173554 | 0.83 | ALOX15 (0.48) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL2889115 | 0.82 | ALOX15 (0.52) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL12463289 | 0.81 | ALOX15 (0.56) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL19526504 | 0.79 | ALOX15 (0.45) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL1352508 | 0.79 | TDP1 (0.54) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL3682215 | 0.79 | TDP1 (0.54) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL11841401 | 0.78 | TDP1 (0.48) | ALOX15TDP1SMN1; SMN2CYP3A4TP53 | |
| SCHEMBL30150898 | 0.78 | AMY1A (0.43) | ALOX15TDP1TP53ALDH1A1HSD17B10 | |
| SCHEMBL233241 | 0.78 | AMY1A (0.43) | ALOX15TDP1TP53ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911795-B1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2025-10-01 | — | — | EP | claimed |
| CN-113646479-B | Method for strengthening non-keratin fibers and use thereof | 埃斯普投资有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-20220120031-A1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2022-04-21 | — | — | US | claimed |
| EP-3911795-A1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP Investments LLC (US) | 2021-11-24 | — | — | EP | claimed |
| CN-113646479-A | Method for strengthening non-keratin fibers and use thereof | 埃斯普投资有限公司 | 2021-11-12 | — | — | CN | claimed |
| EP-3565523-B1 | METHOD FOR COLORING OR BLEACHING HAIR FIBERS | HERCULES LLC (US) | 2021-09-08 | — | — | EP | claimed |
| WO-2020150384-A1 | METHOD OF STRENGTHENING NON-KERATINOUS FIBERS, AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2020-07-23 | — | — | WO | claimed |
| EP-3565523-A1 | METHOD FOR COLORING OR BLEACHING HAIR FIBERS | Hercules LLC (US) | 2019-11-13 | — | — | EP | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| WO-2018129441-A1 | METHOD FOR COLORING OR BLEACHING HAIR FIBERS | HERCULES LLC (US) | 2018-07-12 | — | — | WO | claimed |
| US-7547713-B2 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2009-06-16 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| CN-1284773-C | Ortho-pyridinequinone derivative, composite containing said derivative, its preparation method and application | BAIRUI GLOBAL CO LTD (VG) | 2006-11-15 | — | — | CN | claimed |
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2006-05-25 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| CN-1477099-A | O-pyridinoquinone derivative, composition containing the same, preparation method and use of the same | 百瑞全球有限公司 | 2004-02-25 | — | — | CN | claimed |
| US-6509393-B2 | Phase change inks | XEROX CORPORATION | 2003-01-21 | — | — | US | claimed |
| US-20020137816-A1 | Phase change inks | XEROX CORPORATION | 2002-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | PTGS2, PTGES2, PTGES | ALOX15 227/4885TDP1 3288/4885SMN1; SMN2 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.